Analyst Ratings For Abzena PLC (LON:ABZA)
Today, Numis Securities Ltd reiterated its Buy rating on Abzena PLC (LON:ABZA) with a price target of GBX 90.
There are 1 buy rating on the stock.
The current consensus rating on Abzena PLC (LON:ABZA) is Buy (Score: 3.00) with a consensus target price of GBX 95 per share, a potential .
Some recent analyst ratings include
- 2/21/2017-Numis Securities Ltd Reiterated Rating of Buy.
- 2/21/2017-N+1 Singer Reiterated Rating of Corporate.
- 11/29/2016-FinnCap Reiterated Rating of Buy.
About Abzena PLC (LON:ABZA)
Abzena plc is a life sciences company. The Company provides technologies and complementary services to enable the development and manufacture of biopharmaceutical products. It has a global customer base which includes approximately 20 biopharmaceutical companies, as well as large and small biotech companies and academic groups. It offers immunogenicity assessment, which includes EpiScreen, iTope and T Cell Epitope Database (TCED); antibody drug conjugates, which includes ThioBridge linkers; antibody, which includes Composite Human Antibodies and Composite Proteins; optimization of pharmacokinetics, which includes TheraPEG, HiPEG conjugates PEG to poly-histidine motifs and CyPEG, and PolyPEG; cell line development, which includes Composite Human Antibody; process development, Good manufacturing practices (GMP) manufacturing, and small molecules. The Company’s Abzena inside includes Composite Human Antibodies and ThioBridge Antibody Drug Conjugates (ADCs).
Recent Trading Activity for Abzena PLC (LON:ABZA)
Shares of Abzena PLC closed the previous trading session at 37.35 down -2.15 -5.44% with 0 shares trading hands.